Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences

Rhea-AI Summary

Pieris Pharmaceuticals (NASDAQ:PIRS) announced participation in two upcoming investor conferences. The Jefferies London Healthcare Conference is scheduled for November 18, 2021 at 8:00 AM GMT, with a webcast available. The 4th Annual Evercore ISI HealthCONx Conference will take place on December 1, 2021 at 11:20 AM EST, also featuring a webcast. Pieris focuses on biotherapeutics for respiratory diseases and cancer through its proprietary Anticalin technology.

BOSTON, MA / ACCESSWIRE / November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin^® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences:

Jefferies London Healthcare Conference

Thursday, November 18, 2021 at 8:00 AM GMT. A webcast of the Company's fireside chat will be available at this link.

4th Annual Evercore ISI HealthCONx Conference

Wednesday, December 1, 2021 at 11:20 AM EST. A webcast of the Company's fireside chat will be available at this link.

About Pieris Pharmaceuticals:

Pieris is a clinical-stage biotechnology company that combines leading protein engineering capabilities and deep understanding into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and locally-activated bispecifics for immuno-oncology. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships with leading pharmaceutical companies. For more information, visit www.pieris.com.

Forward Looking Statements:

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, whether the benefits of PRS-344 in treating solid tumors demonstrated in preclinical studies will be seen in the phase 1 study, the expected timing and potential outcomes of the reporting by the Company of key clinical data from its programs, references to novel technologies and methods and our business and product development plans, including the Company's cash resources, the advancement of our proprietary and co-development programs into and through the clinic and the expected timing for reporting data, making IND filings or achieving other milestones related to our programs, including PRS-060/AZD1402, cinrebafusp alfa, PRS-344, and PRS-352 and the expected timing of the initiation of the next stage of cinrebafusp alfa's development in gastric cancer. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; our ability to address the requests of the U.S. Food and Drug Administration; competition in the industry in which we operate; delays or disruptions due to COVID-19; and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the Securities and Exchange Commission available at www.sec.gov, including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and the Company's Quarterly Reports on Form 10-Q.

Investor Relations Contact:

Pieris Pharmaceuticals, Inc.
Maria Kelman
Executive Director, Investor Relations
+1 857 362 9635
kelman@pieris.com

SOURCE: Pieris Pharmaceuticals, Inc.

View source version on accesswire.com:
https://www.accesswire.com/672284/Pieris-Pharmaceuticals-To-Participate-In-Upcoming-Investor-Conferences

FAQ

What are the upcoming investor conferences for Pieris Pharmaceuticals in 2021?

Pieris Pharmaceuticals will participate in the Jefferies London Healthcare Conference on November 18, 2021, at 8:00 AM GMT, and the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 11:20 AM EST.

Where can I find the webcast links for Pieris Pharmaceuticals conferences?

The webcast for the Jefferies London Healthcare Conference can be found at this link, and for the Evercore ISI HealthCONx Conference, it is available at this link.

What is Pieris Pharmaceuticals focusing on in biotherapeutics?

Pieris Pharmaceuticals is advancing novel biotherapeutics for respiratory diseases and cancer through its proprietary Anticalin technology platform.

What is the significance of the upcoming investor conferences for Pieris Pharmaceuticals?

The investor conferences provide Pieris Pharmaceuticals an opportunity to communicate its advancements and strategies to investors, potentially impacting its stock performance.